Stefan Riedel, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anti-Bacterial Agents | 15 | 2021 | 7181 | 1.730 |
Why?
|
Bacteremia | 7 | 2017 | 962 | 1.460 |
Why?
|
Neisseria gonorrhoeae | 5 | 2019 | 238 | 1.380 |
Why?
|
Blood | 5 | 2011 | 598 | 1.250 |
Why?
|
Calcitonin | 4 | 2013 | 336 | 1.220 |
Why?
|
Culture Media | 4 | 2011 | 908 | 1.150 |
Why?
|
Microbial Sensitivity Tests | 12 | 2021 | 1877 | 1.120 |
Why?
|
Fungi | 3 | 2023 | 327 | 1.080 |
Why?
|
Drug Resistance, Multiple, Bacterial | 5 | 2021 | 567 | 1.010 |
Why?
|
Protein Precursors | 4 | 2013 | 1154 | 0.990 |
Why?
|
Drug Resistance, Bacterial | 5 | 2019 | 1035 | 0.990 |
Why?
|
Bacteriological Techniques | 5 | 2019 | 277 | 0.960 |
Why?
|
Mycobacterium | 2 | 2023 | 249 | 0.860 |
Why?
|
Water Microbiology | 3 | 2019 | 117 | 0.820 |
Why?
|
Microbiological Techniques | 2 | 2014 | 102 | 0.800 |
Why?
|
Blood Specimen Collection | 2 | 2016 | 246 | 0.790 |
Why?
|
Reagins | 1 | 2020 | 7 | 0.760 |
Why?
|
Syphilis Serodiagnosis | 1 | 2020 | 35 | 0.740 |
Why?
|
Treponema pallidum | 1 | 2020 | 40 | 0.740 |
Why?
|
Enterococcus | 2 | 2014 | 157 | 0.740 |
Why?
|
Spectinomycin | 1 | 2019 | 9 | 0.700 |
Why?
|
Nebramycin | 1 | 2019 | 10 | 0.690 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2021 | 602 | 0.690 |
Why?
|
Gram-Negative Bacteria | 3 | 2017 | 270 | 0.670 |
Why?
|
Laboratories | 3 | 2021 | 463 | 0.670 |
Why?
|
Bacteria | 4 | 2021 | 2114 | 0.660 |
Why?
|
Disk Diffusion Antimicrobial Tests | 1 | 2017 | 9 | 0.620 |
Why?
|
Enterobacteriaceae | 1 | 2019 | 169 | 0.620 |
Why?
|
Syphilis | 1 | 2020 | 227 | 0.610 |
Why?
|
Coccidioidomycosis | 1 | 2017 | 36 | 0.600 |
Why?
|
Penicillanic Acid | 1 | 2017 | 45 | 0.600 |
Why?
|
Cephalosporins | 2 | 2017 | 204 | 0.590 |
Why?
|
Gram-Negative Bacterial Infections | 2 | 2017 | 232 | 0.590 |
Why?
|
Lung Diseases, Fungal | 1 | 2017 | 122 | 0.570 |
Why?
|
Macrolides | 2 | 2017 | 201 | 0.520 |
Why?
|
Sepsis | 3 | 2016 | 2593 | 0.520 |
Why?
|
Cryptococcosis | 2 | 2015 | 101 | 0.510 |
Why?
|
Prosthesis-Related Infections | 1 | 2020 | 538 | 0.500 |
Why?
|
Urinary Tract Infections | 1 | 2021 | 788 | 0.500 |
Why?
|
Staphylococcus aureus | 2 | 2014 | 1451 | 0.450 |
Why?
|
Virus Diseases | 1 | 2019 | 711 | 0.450 |
Why?
|
Knee Joint | 2 | 2020 | 1680 | 0.440 |
Why?
|
Diagnosis | 1 | 2014 | 154 | 0.440 |
Why?
|
Mycobacterium marinum | 2 | 2017 | 26 | 0.430 |
Why?
|
Silver Nitrate | 1 | 2011 | 12 | 0.420 |
Why?
|
Bacterial Infections | 2 | 2019 | 1401 | 0.420 |
Why?
|
Cryptococcus | 1 | 2011 | 29 | 0.410 |
Why?
|
Diagnostic Tests, Routine | 5 | 2021 | 783 | 0.400 |
Why?
|
Autopsy | 2 | 2021 | 1020 | 0.400 |
Why?
|
Candidemia | 1 | 2011 | 29 | 0.390 |
Why?
|
Gonorrhea | 4 | 2019 | 335 | 0.380 |
Why?
|
Triazoles | 2 | 2015 | 911 | 0.370 |
Why?
|
Trichomonas Infections | 1 | 2010 | 43 | 0.370 |
Why?
|
Candida | 1 | 2011 | 172 | 0.360 |
Why?
|
Calcitonin Gene-Related Peptide | 4 | 2013 | 306 | 0.360 |
Why?
|
Trichomonas vaginalis | 1 | 2010 | 76 | 0.360 |
Why?
|
Melanins | 1 | 2011 | 289 | 0.350 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2020 | 1458 | 0.340 |
Why?
|
Ciprofloxacin | 3 | 2020 | 315 | 0.340 |
Why?
|
Antifungal Agents | 3 | 2020 | 730 | 0.330 |
Why?
|
Anti-Infective Agents | 1 | 2016 | 972 | 0.330 |
Why?
|
Bacterial Typing Techniques | 1 | 2009 | 256 | 0.320 |
Why?
|
Vancomycin Resistance | 1 | 2008 | 128 | 0.310 |
Why?
|
Methicillin Resistance | 1 | 2008 | 198 | 0.310 |
Why?
|
Clinical Laboratory Techniques | 4 | 2021 | 738 | 0.300 |
Why?
|
Burn Units | 2 | 2018 | 136 | 0.300 |
Why?
|
Sensitivity and Specificity | 10 | 2021 | 14722 | 0.280 |
Why?
|
Genotype | 1 | 2021 | 12951 | 0.280 |
Why?
|
Hospitals, Veterans | 1 | 2008 | 404 | 0.270 |
Why?
|
Staphylococcal Infections | 3 | 2010 | 1400 | 0.270 |
Why?
|
Cross Infection | 2 | 2012 | 1416 | 0.260 |
Why?
|
Communicable Diseases | 1 | 2014 | 880 | 0.260 |
Why?
|
Drug Contamination | 1 | 2006 | 147 | 0.250 |
Why?
|
1-Naphthylamine | 1 | 2004 | 49 | 0.250 |
Why?
|
Infant, Newborn, Diseases | 1 | 2010 | 582 | 0.250 |
Why?
|
Carrier State | 1 | 2008 | 518 | 0.250 |
Why?
|
Polymerase Chain Reaction | 3 | 2023 | 6171 | 0.240 |
Why?
|
Sarcina | 1 | 2023 | 10 | 0.240 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7279 | 0.240 |
Why?
|
Quality Control | 2 | 2017 | 841 | 0.230 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2010 | 687 | 0.230 |
Why?
|
Platelet Transfusion | 1 | 2006 | 314 | 0.220 |
Why?
|
Humans | 56 | 2023 | 744343 | 0.220 |
Why?
|
Nucleic Acid Amplification Techniques | 3 | 2021 | 323 | 0.220 |
Why?
|
Fetal Blood | 1 | 2009 | 1318 | 0.210 |
Why?
|
Intensive Care Units | 3 | 2018 | 3679 | 0.210 |
Why?
|
Menisci, Tibial | 1 | 2004 | 269 | 0.210 |
Why?
|
Invasive Pulmonary Aspergillosis | 1 | 2021 | 15 | 0.200 |
Why?
|
Streptococcus pneumoniae | 1 | 2007 | 714 | 0.200 |
Why?
|
Proteus mirabilis | 1 | 2021 | 25 | 0.200 |
Why?
|
Mycoses | 2 | 2017 | 376 | 0.200 |
Why?
|
Mucorales | 1 | 2021 | 33 | 0.200 |
Why?
|
Arthrodermataceae | 1 | 2020 | 7 | 0.200 |
Why?
|
Oils, Volatile | 1 | 2020 | 13 | 0.190 |
Why?
|
Maryland | 2 | 2019 | 276 | 0.190 |
Why?
|
Tetracycline | 2 | 2018 | 214 | 0.190 |
Why?
|
Ceftazidime | 1 | 2020 | 69 | 0.190 |
Why?
|
Pulmonary Aspergillosis | 1 | 2021 | 47 | 0.190 |
Why?
|
Unnecessary Procedures | 2 | 2015 | 432 | 0.190 |
Why?
|
Neutralization Tests | 1 | 2022 | 758 | 0.190 |
Why?
|
Fever | 1 | 2008 | 1616 | 0.180 |
Why?
|
Automation, Laboratory | 1 | 2020 | 101 | 0.180 |
Why?
|
Atlantic Ocean | 1 | 2019 | 27 | 0.170 |
Why?
|
West Virginia | 1 | 2019 | 28 | 0.170 |
Why?
|
Enterococcus faecalis | 1 | 2021 | 251 | 0.170 |
Why?
|
Injections, Intra-Articular | 1 | 2020 | 278 | 0.170 |
Why?
|
Klebsiella pneumoniae | 1 | 2021 | 251 | 0.170 |
Why?
|
Stomach | 1 | 2023 | 697 | 0.170 |
Why?
|
Rivers | 1 | 2019 | 66 | 0.170 |
Why?
|
Nasopharynx | 1 | 2021 | 379 | 0.160 |
Why?
|
Germ Cells | 1 | 2022 | 631 | 0.160 |
Why?
|
Dermatomycoses | 1 | 2018 | 45 | 0.160 |
Why?
|
Disease Outbreaks | 2 | 2018 | 1772 | 0.160 |
Why?
|
Immunoglobulin M | 1 | 2022 | 1537 | 0.150 |
Why?
|
Hyphae | 1 | 2017 | 56 | 0.150 |
Why?
|
Penicillium | 1 | 2017 | 22 | 0.150 |
Why?
|
Spores, Fungal | 1 | 2017 | 94 | 0.150 |
Why?
|
Gloves, Surgical | 1 | 2017 | 26 | 0.150 |
Why?
|
Saliva | 1 | 2021 | 809 | 0.150 |
Why?
|
Respiratory Syncytial Virus Infections | 1 | 2021 | 329 | 0.150 |
Why?
|
Limit of Detection | 3 | 2022 | 265 | 0.140 |
Why?
|
Specimen Handling | 1 | 2021 | 694 | 0.140 |
Why?
|
Cyclonic Storms | 1 | 2018 | 119 | 0.140 |
Why?
|
beta-Lactamases | 1 | 2017 | 306 | 0.130 |
Why?
|
Blood Platelets | 1 | 2006 | 2508 | 0.130 |
Why?
|
Immunoglobulin G | 2 | 2022 | 4560 | 0.130 |
Why?
|
Genes, Bacterial | 1 | 2019 | 1079 | 0.130 |
Why?
|
Antigens, Fungal | 1 | 2015 | 70 | 0.130 |
Why?
|
Clostridium septicum | 1 | 2014 | 2 | 0.130 |
Why?
|
Gas Gangrene | 1 | 2014 | 9 | 0.120 |
Why?
|
Catheter-Related Infections | 1 | 2017 | 252 | 0.120 |
Why?
|
Hemolysis | 1 | 2016 | 420 | 0.120 |
Why?
|
Sentinel Surveillance | 1 | 2016 | 281 | 0.120 |
Why?
|
Antibodies, Bacterial | 1 | 2020 | 1470 | 0.120 |
Why?
|
Phlebotomy | 1 | 2015 | 141 | 0.120 |
Why?
|
Postoperative Care | 1 | 2020 | 1486 | 0.120 |
Why?
|
Refrigeration | 1 | 2013 | 29 | 0.120 |
Why?
|
Preservatives, Pharmaceutical | 1 | 2013 | 31 | 0.120 |
Why?
|
Daptomycin | 1 | 2014 | 73 | 0.120 |
Why?
|
Chromatography, Affinity | 1 | 2015 | 549 | 0.120 |
Why?
|
Oxazolidinones | 1 | 2014 | 96 | 0.110 |
Why?
|
Predictive Value of Tests | 3 | 2019 | 15076 | 0.110 |
Why?
|
Serum Amyloid P-Component | 1 | 2013 | 47 | 0.110 |
Why?
|
Pseudomonas aeruginosa | 1 | 2021 | 1219 | 0.110 |
Why?
|
Pathology, Molecular | 1 | 2016 | 326 | 0.110 |
Why?
|
Thyroglobulin | 1 | 2013 | 114 | 0.110 |
Why?
|
Antibodies, Neutralizing | 1 | 2022 | 1978 | 0.110 |
Why?
|
Equipment Contamination | 1 | 2014 | 185 | 0.110 |
Why?
|
Catheterization, Central Venous | 1 | 2017 | 514 | 0.110 |
Why?
|
Acetamides | 1 | 2014 | 249 | 0.110 |
Why?
|
Acute-Phase Proteins | 1 | 2013 | 262 | 0.100 |
Why?
|
Silver Staining | 1 | 2011 | 64 | 0.100 |
Why?
|
Drug Combinations | 1 | 2017 | 1959 | 0.100 |
Why?
|
Vasopressins | 1 | 2013 | 370 | 0.100 |
Why?
|
Vagina | 1 | 2017 | 825 | 0.100 |
Why?
|
Ascomycota | 1 | 2012 | 82 | 0.100 |
Why?
|
Granulomatous Disease, Chronic | 1 | 2012 | 174 | 0.100 |
Why?
|
Vancomycin | 1 | 2014 | 501 | 0.090 |
Why?
|
Guidelines as Topic | 1 | 2017 | 1405 | 0.090 |
Why?
|
Lung | 2 | 2021 | 9856 | 0.090 |
Why?
|
Blood Coagulation | 1 | 2016 | 1127 | 0.090 |
Why?
|
Interleukin-8 | 1 | 2013 | 690 | 0.090 |
Why?
|
Agar | 1 | 2010 | 56 | 0.090 |
Why?
|
Orthopedic Procedures | 1 | 2020 | 1288 | 0.090 |
Why?
|
Influenza, Human | 1 | 2021 | 1479 | 0.090 |
Why?
|
Antiprotozoal Agents | 1 | 2010 | 86 | 0.090 |
Why?
|
Burns | 2 | 2018 | 1815 | 0.090 |
Why?
|
Metronidazole | 1 | 2010 | 217 | 0.090 |
Why?
|
Outpatients | 1 | 2017 | 1486 | 0.080 |
Why?
|
Urine | 1 | 2010 | 370 | 0.080 |
Why?
|
Male | 15 | 2021 | 350118 | 0.080 |
Why?
|
Middle Aged | 13 | 2021 | 213383 | 0.080 |
Why?
|
Myocardium | 1 | 2021 | 4776 | 0.080 |
Why?
|
Drug Prescriptions | 1 | 2017 | 1637 | 0.080 |
Why?
|
Operating Rooms | 1 | 2014 | 817 | 0.070 |
Why?
|
Retrospective Studies | 5 | 2023 | 77449 | 0.070 |
Why?
|
Gram-Positive Bacteria | 1 | 2008 | 184 | 0.070 |
Why?
|
Temperature | 1 | 2013 | 2206 | 0.070 |
Why?
|
Aged | 9 | 2021 | 163280 | 0.070 |
Why?
|
Infection Control | 1 | 2014 | 966 | 0.070 |
Why?
|
Nasal Cavity | 1 | 2008 | 313 | 0.070 |
Why?
|
Aged, 80 and over | 5 | 2023 | 57776 | 0.070 |
Why?
|
Quality Assurance, Health Care | 1 | 2016 | 2212 | 0.070 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2008 | 341 | 0.070 |
Why?
|
Female | 17 | 2023 | 380194 | 0.070 |
Why?
|
Patient Admission | 2 | 2014 | 1380 | 0.070 |
Why?
|
Kidney | 1 | 2021 | 7186 | 0.070 |
Why?
|
Liver | 1 | 2021 | 7474 | 0.060 |
Why?
|
Pneumonia | 1 | 2017 | 2133 | 0.060 |
Why?
|
Lymphatic Metastasis | 1 | 2013 | 2924 | 0.060 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2009 | 652 | 0.060 |
Why?
|
Ultrasonography | 1 | 2017 | 5985 | 0.060 |
Why?
|
Academic Medical Centers | 1 | 2014 | 2759 | 0.060 |
Why?
|
Clostridium | 1 | 2023 | 98 | 0.060 |
Why?
|
Rectum | 1 | 2008 | 904 | 0.060 |
Why?
|
Interleukin-6 | 1 | 2013 | 3200 | 0.060 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2010 | 1320 | 0.060 |
Why?
|
Drug Evaluation | 1 | 2004 | 647 | 0.060 |
Why?
|
RNA, Viral | 2 | 2021 | 2902 | 0.050 |
Why?
|
Polysaccharides | 1 | 2009 | 1053 | 0.050 |
Why?
|
Membrane Glycoproteins | 1 | 2013 | 3768 | 0.050 |
Why?
|
Viral Load | 2 | 2021 | 3299 | 0.050 |
Why?
|
Decision Support Techniques | 1 | 2012 | 1956 | 0.050 |
Why?
|
Sheep | 1 | 2004 | 1437 | 0.050 |
Why?
|
C-Reactive Protein | 1 | 2013 | 3778 | 0.050 |
Why?
|
Influenza B virus | 1 | 2021 | 50 | 0.050 |
Why?
|
Immunologic Tests | 1 | 2022 | 103 | 0.050 |
Why?
|
Adult | 9 | 2021 | 214055 | 0.050 |
Why?
|
Microsporum | 1 | 2020 | 5 | 0.050 |
Why?
|
Fluoroquinolones | 2 | 2017 | 310 | 0.050 |
Why?
|
Carcinoma | 1 | 2013 | 2375 | 0.050 |
Why?
|
Trichophyton | 1 | 2020 | 17 | 0.050 |
Why?
|
Antibodies | 1 | 2009 | 2460 | 0.050 |
Why?
|
Acute Coronary Syndrome | 1 | 2014 | 2337 | 0.050 |
Why?
|
Time Factors | 4 | 2015 | 40075 | 0.050 |
Why?
|
Europe | 1 | 2007 | 3339 | 0.050 |
Why?
|
Photosensitizing Agents | 1 | 2004 | 602 | 0.050 |
Why?
|
Adolescent | 4 | 2014 | 85781 | 0.040 |
Why?
|
Carrier Proteins | 1 | 2013 | 5021 | 0.040 |
Why?
|
Atlases as Topic | 1 | 2021 | 236 | 0.040 |
Why?
|
Time | 1 | 2021 | 542 | 0.040 |
Why?
|
Knee Injuries | 1 | 2004 | 490 | 0.040 |
Why?
|
Thyroid Neoplasms | 1 | 2013 | 2282 | 0.040 |
Why?
|
Algorithms | 1 | 2020 | 13881 | 0.040 |
Why?
|
Infant, Newborn | 2 | 2010 | 25625 | 0.040 |
Why?
|
Respiratory Syncytial Virus, Human | 1 | 2021 | 139 | 0.040 |
Why?
|
Phagocytes | 1 | 2021 | 297 | 0.040 |
Why?
|
Expert Testimony | 1 | 2021 | 356 | 0.040 |
Why?
|
Obesity | 1 | 2020 | 12745 | 0.040 |
Why?
|
Pulmonary Alveoli | 1 | 2021 | 675 | 0.040 |
Why?
|
Influenza A virus | 1 | 2021 | 456 | 0.040 |
Why?
|
Models, Animal | 1 | 2004 | 2171 | 0.040 |
Why?
|
Baltimore | 1 | 2018 | 231 | 0.040 |
Why?
|
Laser Therapy | 1 | 2004 | 1072 | 0.040 |
Why?
|
Amikacin | 1 | 2017 | 48 | 0.040 |
Why?
|
United States | 6 | 2021 | 69872 | 0.040 |
Why?
|
Cefoxitin | 1 | 2017 | 36 | 0.040 |
Why?
|
Inflammation | 2 | 2021 | 10638 | 0.040 |
Why?
|
Clarithromycin | 1 | 2017 | 86 | 0.040 |
Why?
|
Risk Factors | 2 | 2020 | 72290 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2011 | 12959 | 0.030 |
Why?
|
Phylogeny | 1 | 2023 | 2803 | 0.030 |
Why?
|
Emergency Service, Hospital | 2 | 2017 | 7659 | 0.030 |
Why?
|
Organ Specificity | 1 | 2021 | 2008 | 0.030 |
Why?
|
Biological Specimen Banks | 1 | 2021 | 711 | 0.030 |
Why?
|
Canada | 1 | 2021 | 2065 | 0.030 |
Why?
|
Cities | 1 | 2017 | 513 | 0.030 |
Why?
|
Peru | 1 | 2017 | 881 | 0.030 |
Why?
|
Treatment Outcome | 1 | 2020 | 63114 | 0.030 |
Why?
|
Hematologic Tests | 1 | 2015 | 240 | 0.030 |
Why?
|
Uganda | 1 | 2018 | 1243 | 0.030 |
Why?
|
Penicillins | 1 | 2016 | 380 | 0.030 |
Why?
|
Fasciitis, Necrotizing | 1 | 2014 | 79 | 0.030 |
Why?
|
Serum | 1 | 2015 | 214 | 0.030 |
Why?
|
Utilization Review | 1 | 2015 | 392 | 0.030 |
Why?
|
Hospital Charges | 1 | 2014 | 362 | 0.030 |
Why?
|
Regeneration | 1 | 2021 | 1485 | 0.030 |
Why?
|
Cerebrospinal Fluid | 1 | 2015 | 534 | 0.030 |
Why?
|
Ileum | 1 | 2014 | 565 | 0.030 |
Why?
|
Immunoenzyme Techniques | 1 | 2015 | 1799 | 0.020 |
Why?
|
Gynecology | 1 | 2017 | 513 | 0.020 |
Why?
|
Bronchiolitis | 1 | 2017 | 458 | 0.020 |
Why?
|
Iatrogenic Disease | 1 | 2014 | 547 | 0.020 |
Why?
|
Health Resources | 1 | 2017 | 911 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2021 | 2183 | 0.020 |
Why?
|
Ambulatory Care Facilities | 1 | 2017 | 933 | 0.020 |
Why?
|
Fibroblasts | 1 | 2021 | 4161 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2006 | 19229 | 0.020 |
Why?
|
Obstetrics | 1 | 2017 | 658 | 0.020 |
Why?
|
Respiratory Tract Infections | 1 | 2017 | 961 | 0.020 |
Why?
|
Education, Medical, Continuing | 1 | 2015 | 840 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2014 | 1850 | 0.020 |
Why?
|
Proton Pump Inhibitors | 1 | 2014 | 526 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 2015 | 1681 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2021 | 3690 | 0.020 |
Why?
|
Area Under Curve | 1 | 2013 | 1654 | 0.020 |
Why?
|
Pregnancy | 1 | 2010 | 29144 | 0.020 |
Why?
|
Databases, Factual | 1 | 2023 | 7729 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2021 | 3479 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 11524 | 0.020 |
Why?
|
Biopsy, Fine-Needle | 1 | 2013 | 1094 | 0.020 |
Why?
|
Heart | 1 | 2021 | 4467 | 0.020 |
Why?
|
Carcinoma, Papillary | 1 | 2013 | 783 | 0.020 |
Why?
|
Linear Models | 1 | 2017 | 5952 | 0.020 |
Why?
|
Young Adult | 2 | 2014 | 56430 | 0.020 |
Why?
|
Microarray Analysis | 1 | 2009 | 767 | 0.020 |
Why?
|
Patient Care Team | 1 | 2017 | 2531 | 0.020 |
Why?
|
Radiography | 1 | 2017 | 7023 | 0.020 |
Why?
|
Taxoids | 1 | 2009 | 666 | 0.020 |
Why?
|
ROC Curve | 1 | 2013 | 3527 | 0.020 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 2282 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2017 | 12245 | 0.010 |
Why?
|
Guideline Adherence | 1 | 2014 | 2266 | 0.010 |
Why?
|
Pilot Projects | 1 | 2017 | 8324 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 2009 | 2242 | 0.010 |
Why?
|
Doxorubicin | 1 | 2009 | 2234 | 0.010 |
Why?
|
Quality Improvement | 1 | 2017 | 3749 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2021 | 12261 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2009 | 20822 | 0.010 |
Why?
|
Pyrimidines | 1 | 2012 | 2942 | 0.010 |
Why?
|
Receptor, erbB-2 | 1 | 2009 | 2416 | 0.010 |
Why?
|
Asthma | 1 | 2017 | 6011 | 0.010 |
Why?
|
Prospective Studies | 2 | 2015 | 53288 | 0.010 |
Why?
|
Hospitalization | 1 | 2015 | 10262 | 0.010 |
Why?
|
Infant | 1 | 2017 | 35136 | 0.010 |
Why?
|
Child, Preschool | 1 | 2017 | 41006 | 0.010 |
Why?
|
Animals | 1 | 2004 | 168757 | 0.010 |
Why?
|
HIV Infections | 1 | 2018 | 16718 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2009 | 39050 | 0.000 |
Why?
|